ABSTRACT: It is well known that polymeric prodrug or polymer-drug conjugate is an effective and fast growing technique for improved use of. Polymer therapeutics include: rationally designed macromolecular drugs, polymer–drug and polymer–protein conjugates, polymeric micelles containing covalently bound drug, and polyplexes for DNA delivery. Polymer-drug conjugates are now used in cancer therapy, but potential future applications are far-ranging, including diabetes, hypertension, infections, digestive.
|Author:||Isobel Wiegand Sr.|
|Published:||26 May 2015|
|PDF File Size:||40.70 Mb|
|ePub File Size:||11.1 Mb|
|Uploader:||Isobel Wiegand Sr.|
Critical Reviews™ in Therapeutic Drug Carrier Systems
PDCs have shown enhanced tumor accumulation, increased therapeutic index, and prolonged circulation, accompanied by a sustained release of the bound drug.
Information about reproducing material from RSC articles with different licences is available on our Permission Requests page. Search articles by author. Such conjugates usually accumulate in tumors and can reduce toxicity in the body.
Depending on the desired location, polymer conjugates can be synthesized to either have degradable or polymer drug conjugates chemical bonds with their associated drug.
Star Polymer-Drug Conjugates with pH-Controlled Drug Release and Carrier Degradation
To obtain many of many of these bonds the use of peptides or amino acids. To obtain many of many of these bonds the use of peptides or amino acids.
There is a strong desire to synthesize polymeric conjugates with bioactive components and other drugs. The tendency of polymer drug conjugate to react with the proper type cell s needs to still be worked on, despite many current advances.
The functionality of copolymer P3, prepared by RAFT polymerization, close to unity minimized the possibility of crosslinking reactions during the formation of the star copolymer and therefore led to the preparation of star polymer precursor with low dispersity. The linear polymer precursor P4 with hydrazide groups was prepared by FRP and used as a precursor for the synthesis of a control polymer-DOX conjugate P5.
The concentration of DOX 9. The linear conjugate P5 was purified by gel filtration and contained less than 0. All physicochemical characteristics of the prepared polymer precursors are summarized in Table 1.
Synthesis of HMW Polymer Precursors and Conjugate HMW polymers suitable for the passive targeting of tumor tissue and delivery of anticancer drugs into tumors and tumor cells were designed and synthesized. Semitelechelic polymers containing amino end groups were used as polymer grafts attached via amide bonds to the bis-MPA dendrimer core to form star-like molecular structures with synthesis-controlled molecular weights.
The molar ratio of polymer P2 to dendrimer in the conjugation reaction was The lower yield in the reaction of S2 was likely polymer drug conjugates by steric hindrance of the polymer molecules accessing the relatively dense, carboxyl-containing dendrimer core.
The molecular weights of star polymers S1 and S2 reflect the idea that 9 polymer chains polymer drug conjugates grafted in the polymer conjugate of S1 and approximately polymers were grafted in that of S2.
Polymeric conjugates for drug delivery
The genesis of the HMW carrier led to a 3-fold increase in the hydrodynamic radius from approximately nm, corresponding to the linear polymer precursor, to 12—17 nm for the star polymers. The Boc-protected hydrazide polymer drug conjugates in the star copolymers were deprotected with TFA, and we confirmed that neither nor changed during deprotection.
Polymer drug conjugates size of the star polymers fulfilled the prerequisite criteria mentioned in literature that are necessary for the achievement of enhanced passive accumulation of polymers in solid tumors due to the EPR effect.
Physicochemical characteristics of HMW copolymers and drug conjugate.
Star polymer S3 was synthesized in the same manner as previously described for star polymer S1 using semitelechelic polymer P3 prepared by controlled RAFT polymerization and a ratio of polymer to dendrimer core of polymer drug conjugates The dispersity of polymer S3 was below 1.
As expected, of S3 of 12 nm was similar to that observed for S1 and was again 3 times higher polymer drug conjugates that of the linear polymer P3.
Thus, a hydrazide group-containing HMW star polymer carrier polymer drug conjugates low dispersity was successfully synthesized. The HMW star polymer-drug conjugate S4 was subsequently prepared for forthcoming physicochemical and biological experiments, namely, in vitro studies.
- Polymer-drug conjugates - Wikipedia
- Polymeric conjugates for drug delivery
- There was a problem providing the content you requested
- Journal of Nanomaterials
- Publication details
The deprotected hydrazide groups of the star polymer precursor S3 were used for polymer drug conjugates attachment of DOX via pH-sensitive hydrazone bonds in polymer drug conjugates presence of acetic acid. The design and chemistry used for the synthesis of various conjugates will be presented with additional comments on their potential applications and current developmental status.
The design and chemistry used for the synthesis of various conjugates will be polymer drug conjugates with additional comments on their potential applications and current developmental status.